Brokerages Anticipate Fennec Pharmaceuticals Inc (NASDAQ:FENC) Will Announce Earnings of -$0.13 Per Share

Equities research analysts expect Fennec Pharmaceuticals Inc (NASDAQ:FENCGet Rating) to report ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Fennec Pharmaceuticals’ earnings. Fennec Pharmaceuticals reported earnings per share of ($0.18) during the same quarter last year, which would indicate a positive year-over-year growth rate of 27.8%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Fennec Pharmaceuticals will report full-year earnings of ($0.42) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of $0.15 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Fennec Pharmaceuticals.

Fennec Pharmaceuticals (NASDAQ:FENCGet Rating) last released its quarterly earnings data on Monday, February 28th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $3.52 by ($3.70).

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Fennec Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Wedbush reissued an “outperform” rating on shares of Fennec Pharmaceuticals in a research report on Wednesday, April 27th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $11.13.

Shares of Fennec Pharmaceuticals stock opened at $5.76 on Wednesday. The firm has a 50-day moving average of $5.80 and a 200-day moving average of $5.91. Fennec Pharmaceuticals has a 52-week low of $2.90 and a 52-week high of $6.55. The company has a debt-to-equity ratio of 0.32, a current ratio of 13.53 and a quick ratio of 13.54.

A number of hedge funds have recently bought and sold shares of the stock. DG Capital Management LLC raised its stake in Fennec Pharmaceuticals by 5.0% in the third quarter. DG Capital Management LLC now owns 618,451 shares of the company’s stock valued at $5,826,000 after purchasing an additional 29,678 shares in the last quarter. Harbert Fund Advisors Inc. raised its stake in Fennec Pharmaceuticals by 44.6% during the third quarter. Harbert Fund Advisors Inc. now owns 174,750 shares of the company’s stock worth $1,646,000 after acquiring an additional 53,899 shares in the last quarter. Morgan Stanley raised its stake in Fennec Pharmaceuticals by 6.0% during the second quarter. Morgan Stanley now owns 43,430 shares of the company’s stock worth $316,000 after acquiring an additional 2,453 shares in the last quarter. Hartford Financial Management Inc. raised its stake in Fennec Pharmaceuticals by 20.8% during the fourth quarter. Hartford Financial Management Inc. now owns 34,848 shares of the company’s stock worth $153,000 after acquiring an additional 6,000 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Fennec Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 19,909 shares of the company’s stock worth $187,000 after acquiring an additional 1,983 shares in the last quarter. 43.62% of the stock is owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile (Get Rating)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Read More

Get a free copy of the Zacks research report on Fennec Pharmaceuticals (FENC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.